Diversified Trust CO Affimed N.V. Transaction History

Diversified Trust CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 07, 2023	BUY	$0.66 - $1.29 $13,508 - $26,403	20,468 Added 39.63%	72,119 $54,000
Q4 2022 Jan 17, 2023	BUY	$1.1 - $2.45 $27,971 - $62,301	25,429 Added 96.98%	51,651 $64,000
Q3 2022 Oct 14, 2022	SELL	$1.96 - $3.32 $64,993 - $110,091	-33,160 Reduced 55.84%	26,222 $54,000
Q2 2022 Jul 12, 2022	BUY	$2.27 - $4.86 $134,797 - $288,596	59,382 New	59,382 $164,000
Q1 2022 Apr 07, 2022	SELL	$3.69 - $5.65 $61,582 - $94,292	-16,689 Closed	0 $0
Q1 2021 May 10, 2021	SELL	$5.12 - $8.48 $1,064 - $1,763	-208 Reduced 1.23%	16,689 $132,000
Q4 2020 Jan 08, 2021	BUY	$3.16 - $7.03 $3,118 - $6,938	987 Added 6.2%	16,897 $98,000
Q2 2020 Jul 07, 2020	BUY	$1.58 - $4.63 $25,137 - $73,663	15,910 New	15,910 $73,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Diversified Trust CO, based on Form 13F filings with the SEC.

Stay updated on Diversified Trust CO with notifications on news.